Ameritas Investment Partners’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-5,985
| Closed | -$143K | – | 3361 |
|
|
2021
Q1 | $143K | Hold |
5,985
| – | – | 0.01% | 1436 |
|
|
2020
Q4 | $87K | Hold |
5,985
| – | – | ﹤0.01% | 1658 |
|
|
2020
Q3 | $85K | Hold |
5,985
| – | – | ﹤0.01% | 1537 |
|
|
2020
Q2 | $88K | Buy |
5,985
+2,256
| +60% | +$22.9K | ﹤0.01% | 1493 |
|
|
2020
Q1 | $15K | Hold |
3,729
| – | – | ﹤0.01% | 2355 |
|
|
2019
Q4 | $18K | Hold |
3,729
| – | – | ﹤0.01% | 2473 |
|
|
2019
Q3 | $23K | Hold |
3,729
| – | – | ﹤0.01% | 2328 |
|
|
2019
Q2 | $24K | Hold |
3,729
| – | – | ﹤0.01% | 2356 |
|
|
2019
Q1 | $26K | Hold |
3,729
| – | – | ﹤0.01% | 2259 |
|
|
2018
Q4 | $18K | Hold |
3,729
| – | – | ﹤0.01% | 2416 |
|
|
2018
Q3 | $27K | Hold |
3,729
| – | – | ﹤0.01% | 2368 |
|
|
2018
Q2 | $24K | Hold |
3,729
| – | – | ﹤0.01% | 2422 |
|
|
2018
Q1 | $20K | Hold |
3,729
| – | – | ﹤0.01% | 2431 |
|
|
2017
Q4 | $16K | Hold |
3,729
| – | – | ﹤0.01% | 2567 |
|
|
2017
Q3 | $36K | Hold |
3,729
| – | – | ﹤0.01% | 2080 |
|
|
2017
Q2 | $44K | Hold |
3,729
| – | – | ﹤0.01% | 1997 |
|
|
2017
Q1 | $48K | Buy |
+3,729
| New | +$44.9K | ﹤0.01% | 1884 |
|
Ameritas Investment Partners's GNMK Position: Q2 2021 in Review
Ameritas Investment Partners sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 5,985 shares — an estimated $143K sold.
Ameritas Investment Partners first reported a position in GNMK in Q1 2017 and held it in 17 quarters. The position peaked at $143K in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Ameritas Investment Partners reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Ameritas Investment Partners sold 5,985 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $143K.
- Ameritas Investment Partners first reported a position in GenMark Diagnostics, Inc in Q1 2017 and held it in 17 quarters.
- Ameritas Investment Partners's GenMark Diagnostics, Inc position peaked at $143K in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.